Midazolam

Midazolam, Nayzilam, Buccolam (midazolam) is a small molecule pharmaceutical. Midazolam was first approved as Midazolam on 2011-09-04. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy. It is known to target Alpha-1B adrenergic receptor, thyrotropin-releasing hormone receptor, and cytochrome P450 3A4. Midazolam's patents are valid until 2038-06-20 (FDA).